Abstract: An apparatus and method for providing ML processing for one or more ML applications operating on one or more Internet of Things (IoT) devices includes receiving a ML request from an IoT device. The ML request can be generated by a ML application operating on the IoT device and include input data collected by the first ML application. A ML model to perform ML processing of the input data included in the ML request is identified and provided to an ML core for ML processing along with the input data included in the first ML request. The ML core produces ML processing output data based on ML processing by the ML core of input data included in the ML request using the ML model. The ML processing output data can be transmitted to the IoT device.

Abstract: An apparatus and method for providing ML processing for one or more ML applications operating on one or more Internet of Things (IoT) devices includes receiving a ML request from an IoT device. The ML request can be generated by a ML application operating on the IoT device and include input data collected by the first ML application. A ML model to perform ML processing of the input data included in the ML request is identified and provided to an ML core for ML processing along with the input data included in the first ML request. The ML core produces ML processing output data based on ML processing by the ML core of input data included in the ML request using the ML model. The ML processing output data can be transmitted to the IoT device.

Abstract: A night light supported by a toilet seat assembly for directing illumination toward a toilet bowl.

Abstract: A night light supported by a toilet seat assembly for directing illumination toward a toilet bowl.

Abstract: A night light supported by a toilet seat assembly for directing illumination toward a toilet bowl.

Abstract: A night light supported by a toilet seat assembly for directing illumination toward a toilet bowl.

Abstract: A hat, an attachment device, and a mirror are provided. The attachment device may attach the mirror to the hat. The attachment device may include a first loop shaped portion which is configured to be placed around a top portion of the hat. The attachment device may include an elongated member having a length and a width, with the length substantially greater than the width. A first end of the elongated member may be attached to the mirror and an opposing second end may be pivotally attached to the first portion. The attachment device may attach the mirror to the hat so that a reflective surface of the mirror can be seen by a person wearing the hat on a head of the person, when the attachment device is in a first state, and cannot be seen by the person when the attachment device is in a second state.

Abstract: A method of treating cancer by administering a therapeutically effective amount of a compound represented by the following Formula (I), or salt, hydrate, or solvate thereof; wherein: n represents a number from 3 to 7; m represents a number from 1 to 2; R1 and R2 independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number of carbon atoms represented by R1 and R2 when taken together is no less than 5 and no greater than 10; or R1 and R2 together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms; R3 and R4 independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbyl radical.

Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.

Abstract: A method of analysing a sequence of images of a deformable object in non-rigid motion involves modeling the boundary using a non-rigid contour. A representation of movement of the contour through the sequence of images is calculated using a tracking space shape. The calculated movement representation is decomposed using an interpretational space shape that is different than the tracking space shape.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

Abstract: A method of treating cancer by administering a therapeutically effective amount of a compound represented by the following Formula (I), or salt, hydrate, or solvate thereof: wherein: n represents a number from 3 to 7; m represents a number from 1 to 2; R1 and R2 independently represent a hydrogen atom or are a substituted or unsubstituted, branched or unbranched or cyclic, alkyl provided that the total number of carbon atoms represented by R1 and R2 when taken together is no less than 5 and no greater than 10; or R1 and R2 together independently represent a cyclic alkyl group having no less than 3 or no more than 7 carbon atoms; R3 and R4 independently represent a hydrogen atom or a saturated or unsaturated, substituted or unsubstituted, branched or unbranched or cyclic, hydrocarbyl radical.

Abstract: A catalyst composition containing a zeolite and platinum, and a method of preparing such catalyst composition, are disclosed. The thus-obtained catalyst composition is employed in the conversion of a hydrocarbon to aromatics.

Abstract: A catalytic material is provided which effectuates the aromatization, reformation, and dehydrogenation of aliphatic, cycloaliphatic, and mixtures of aliphatic and cycloaliphatic hydrocarbons. The catalyst comprises an L-zeolite associated with a Group VIII metal such as platinum and having a rare earth metal ion incorporated therein. A method of using the catalytic material is also provided.

Abstract: A catalytic material is provided which effectuates the aromatization, reformation, and dehydrogenation of aliphatic, cycloaliphatic, and mixtures of aliphatic and cycloaliphatic hydrocarbons. The catalyst comprises an L-zeolite associated with a Group VIII metal such as platinum and having a rare earth metal ion incorporated therein. A method of using the catalytic material is also provided.

Abstract: A catalytic material is provided which effectuates the aromatization, reformation, and dehydrogenation of aliphatic, cycloaliphatic, and mixtures of aliphatic and cycloaliphatic hydrocarbons. The catalyst comprises an L-zeolite associated with a Group VIII metal such as platinum and having a rare earth metal ion incorporated therein. A method of using the catalytic material is also provided.

Abstract: The present invention provides an exercise bar for use in rehabilitative therapy of joint structures, especially those of an impaired limb of a user. The exercise bar preferably comprises an elongated shaft having a longitudinal axis and two ends, a loop member comprising a loop attached to a first end of the shaft, and a handle member attached to a second end of the shaft at an angle to both the longitudinal axis of the shaft and the plane defined by the loop of the loop member. The loop preferably is in the shape of an isosceles triangle with the angles forming arcuated notches for receiving a portion of the user's impaired limb. Once the user's limb is seated within one of the notches, the shaft may be rotated about it axis to enable rotational, resistive stretching of a first joint complex or may be reciprocated along its axis to enable the performance of various exercises.